Cel Construction and demonstration of a multiple DNA sythesizer prototype to enable diagnostic laboratories to produce many nucleotides simultaneously, on a user friendly simply operated device cost reduction for synthesis of oligonucleotides for clinical and diagnostic purposes. to provide molecular diagnostic tools for clinical applications, e.g.: fluorescent and chemiluminescent based systems for the diagnosis of neurodegenerative disorders due to CAG-repeat expansions reverse dot-blot chemiluminescent based systems for the diagnosis of cystic fibrosis in the different regions of Europe. Production of cheap dye-labelled microsatellite marker sets for automatic genetic mapping of the human genome. Analysis of mutations occuring during tumour development, devising new medical treatment and identifying risk factors.Clinical laboratories will need synthesizers which can produce many different oligonucleotides simultaneously, in a fast and inexpensive way. The current standard synthesis technology is limited to synthesis of 3-4 oligonucleotides simultaneously The high price per oligonucleotide renders extensive clinical analyses expensive. Today's synthesis chemistry and synthesizer technology are not suited to meet future demands. To meet these demands fast multiple DNA synthesizers resulting in low cost oligonucleotides, are required. Based on the concept of the EMBL synthesizer the production of an industrial prototype of a 10 column device, with optional upscaling to 25-40 columns, is one main goal of the project. The technology will reduce DNA synthesis costs by a factor of 10, while increasing the throughput by nearly an order of magnitude compared to standard commercial devices. Among the use of oligonucleotides as a diagnostic tool the most important is their role in PCR as primers for the amplification of specific loci as the previous step in the analysis a given gene or region of the genome. The scope of PCR in clinical diagnosis covers mainly genetic disorders, infectious diseases, and cancer. In the field of infectious diseases, we are entering a period where the diagnosis is becoming more and more molecular, based on the use of PCR and oligonucleotide sequences. The performance of the new synthesizer in molecular medicine will be demonstrated in activities resulting in molecular diagnostic tools for several clinical applications: a) Fluorescent and chemiluminescent based systems for the diagnosis of neurodegenerative disorders due to CAG-repeat expansions. b) Reverse dot-blot chemiluminescent based systems for the diagnosis of cystic fibrosis in the different regions of Europe. c) Inexpensive dye-labelled microsatellite marker sets for automatic genetic mapping of the human genome. cl) Analysis of mutations occurring during tumour development, devising new medical treatment and identifying risk factors. Dziedzina nauki natural sciencesbiological sciencesgeneticsDNAmedical and health scienceshealth sciencesinfectious diseasesnatural sciencesbiological sciencesgeneticsmutationmedical and health sciencesclinical medicineoncologynatural sciencesbiological sciencesgeneticsgenomes Program(-y) FP4-BIOMED 2 - Specific research, technological development and demonstration programme in the field of biomedicine and health, 1994-1998 Temat(-y) 8.2 - Demonstration Zaproszenie do składania wniosków Data not available System finansowania CSC - Cost-sharing contracts Koordynator EUROPEAN MOLECULAR BIOLOGY LABORATORY Wkład UE Brak danych Adres Meyerhofstrasse 1 69117 HEIDELBERG Niemcy Zobacz na mapie Koszt całkowity Brak danych Uczestnicy (3) Sortuj alfabetycznie Sortuj według wkładu UE Rozwiń wszystko Zwiń wszystko Hôpitaux Universitaires de Strasbourg Francja Wkład UE Brak danych Adres Avenue Molière 67098 Hautepierre Zobacz na mapie Koszt całkowity Brak danych Institut de Recerca Oncologica Hiszpania Wkład UE Brak danych Adres KM 2,7,AUTOVIA DE CASTELLDEFELS 08907 BARCELONA Zobacz na mapie Koszt całkowity Brak danych MWG-Biotech GmbH Niemcy Wkład UE Brak danych Adres 30,RUDOLF-WISSELL-STR. 37079 GOTTINGEN Zobacz na mapie Koszt całkowity Brak danych